EKF Diagnostics FY bolstered by 'significantly improved' trading in October

Point-of-care business EKF Diagnostics said on Friday that its full-year performance remained in-line with management expectations.

EKF stated trading in October was anticipated to demonstrate "continued and strong" overall growth as a "significantly improved" performance from its core business and a record month in terms of both revenue and profits underpinned its confidence in a second-half recovery.

While the AIM-listed firm said it was too early to make further revisions to its full-year performance expectations, EKF added that the solid trading in October did suggest a strong fourth-quarter performance.

Elsewhere, EKF noted that PrimeStore MTM, its Covid-19 sample collection device, was successfully evaluated for effective SARS-CoV-2 inactivation in a study published by Public Health England.

EKF highlighted that the study showed that of the few transport reagents, where no residual virus was detectable, PrimeStore MTM was the only commercially available CE-marked and FDA cleared transport media.

As of 1050 BST, EKF shares were down 1.64% at 60.49p.